in vivo News and Research

RSS

Nanomedicine offers targeted solutions for breast cancer treatment

Breast cancer (BCA) is one of the most common cancers worldwide, with high mortality and morbidity in women.

10 Apr 2026

New hippocampus model advances understanding of Alzheimer’s progression

With a new model of the brain region essential to memory formation, from cells to whole-brain networks, the team hopes to identify critical changes in the progression of Alzheimer's disease that could point the way to earlier, more effective treatments.

9 Apr 2026

Wireless ureteral stent sleeve enables early detection of hydronephrosis

Ureteral stents are widely used to relieve obstruction and protect kidney function, but they can also become blocked, triggering hydronephrosis and prolonged elevation of intrarenal pressure that may impair renal function.

9 Apr 2026

Dynamic binding of linker histone H1 shapes flexible chromatin organization

DNA inside the nucleus is not packed as a rigid regular fiber-linker histone H1 dynamically binds and loosely "glues" nucleosomes together, creating a dynamic, fluid organization that can still support essential genome functions.

9 Apr 2026

Microplastics found in human bile may be associated with gallstones

Findings show microplastics in bile may trigger cellular senescence, suggesting a link to gallstone disease and highlighting the need for further research.

9 Apr 2026

Virica Biotech and FUJIFILM Biosciences collaborate under the Canada-Japan Co-Innovation Program to advance AAV production enhancers

Virica Biotech ("Virica"), a cell enhancer company specializing in Viral Sensitizers (VSE™) for viral vector manufacturing, today announced it is receiving advisory services and funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP), under the Canada-Japan Corporate Co-Innovation Program for a collaboration with FUJIFILM Biosciences.

From Virica Biotech 9 Apr 2026

Insilico Medicine nominates AI-driven drug candidate for cancer, Cushing's syndrome and obesity

The NR3C1 (nuclear receptor subfamily 3 group C member 1) gene encodes the glucocorticoid receptor (GR), a nuclear receptor vital for maintaining physiological homeostasis, and inhibition of NR3C1 could increase the sensitivity of cancer cells to standard chemotherapy, particularly in ovarian cancer.

8 Apr 2026

Clusterin inhibition offers new hope for treating cervical gastric-type adenocarcinoma

Gastric-type adenocarcinoma (GAS) is one of the most aggressive non-human papillomavirus (HPV)-associated cervical adenocarcinomas and remains especially difficult to diagnose and treat.

8 Apr 2026

Future CAR therapy expands beyond T cells to treat diverse diseases

CAR-T therapy has transformed treatment for some blood cancers, with seven FDA-approved products and strong clinical responses in hematologic malignancies.

8 Apr 2026

Xuebijing injection reduces inflammation and ferroptosis in acute lung injury

Using an LPS-induced ALI mouse model and LPS-stimulated alveolar macrophages, they found XBJ reduced inflammatory cytokine surges, preserved alveolar barrier integrity, and limited tissue injury, while probing the molecular pathways and intracellular targets underlying these benefits.

7 Apr 2026

Study questions benefits of fish oil after mild brain injuries

A first-of-its-kind study led by the Medical University of South Carolina raises questions about the value of fish oil supplements for people with repetitive mild traumatic brain injuries.

7 Apr 2026

Blocking nitric oxide suppresses tumor growth in aggressive pediatric neuroblastoma

The tumor begins before birth. Somewhere in the developing fetus, neural crest cells that should have matured into adrenal tissue or sympathetic ganglia take a wrong turn, and a child is born harboring a malignancy that may not declare itself for months.

7 Apr 2026

Prickly pear may pack a surprising punch against metabolic syndrome

This narrative review examines how Opuntia ficus-indica fruit, or prickly pear, may help target multiple features of metabolic syndrome through its fiber, betalains, polyphenols, carotenoids, and other bioactive compounds. The authors conclude that the fruit shows promising mechanistic and preclinical potential, but stronger human trials are still needed before firm clinical claims can be made.

6 Apr 2026

AI helps researchers find antimicrobial peptides in Earth’s harshest habitats

Researchers built the Extreme Environment Microbiome Catalog from 78,213 genomes across global extreme habitats, revealing major taxonomic and biosynthetic novelty, including 32,715 representative species, nearly 4 billion non-redundant genes, and 163,693 biosynthetic gene clusters. They then used protein language models to identify 3,032 candidate non-toxic antimicrobial peptides, with 84 of 100 synthesized peptides showing antibacterial activity and low cytotoxicity in the 50 tested in mammalian cells.

6 Apr 2026

Small molecule may block protein buildup in neurodegenerative diseases

A team of researchers from NYU Abu Dhabi and the University of Denver have identified a promising small molecule that could help slow or halt the progression of serious brain diseases such as Parkinson's disease, offering new hope for treatments that go beyond managing symptoms.

1 Apr 2026

New therapy reprograms immune cells to reduce asthma inflammation

A collaborative effort between researchers at the Henan Academy of Innovations in Medical Science, Zhengzhou University, and Shenzhen University School of Medicine has provided the first proof-of-principle study demonstrating that targeting a receptor on the surface of anti-inflammatory regulatory T cells (Tregs) can restore their function and alleviate asthma in mice.

31 Mar 2026

Lipid nanoparticles help CAR T cells melt pancreatic cancer barriers

Often diagnosed when surgery is no longer an option, pancreatic cancer is one of the most difficult cancers to treat and has one of the lowest rates of survival among major malignancies.

31 Mar 2026

Collaboration advances EMA601 as potential first-in-class stroke therapy

Boehringer Ingelheim and the Lower Franconian biotech company EMFRET Analytics have signed a cooperation and license agreement for the preclinical development program of the GPVI‑blocking antibody EMA601.

30 Mar 2026

Natural peptide in sweat may help block flu infection before symptoms start

Researchers led by the Fisabio Foundation found that dermcidin, a natural antimicrobial peptide present in sweat and respiratory tissues, can block influenza infection by binding to a highly conserved region of the viral hemagglutinin protein and preventing cell entry. The study also found that people who did not develop flu-like symptoms had markedly higher baseline dermcidin levels, suggesting the molecule may help reduce susceptibility to infection and could support the development of broader-spectrum antivirals.

30 Mar 2026

Nuclera launches GPCR-focused nanodisc panel to streamline membrane protein production

Nuclera, the biotechnology company enabling rapid access to high-quality proteins, today announced the launch of its nanodisc panel to support screening and scale-up of G-Protein Coupled Receptors (GPCRs).

From Nuclera 30 Mar 2026